<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00275457</url>
  </required_header>
  <id_info>
    <org_study_id>248.520</org_study_id>
    <nct_id>NCT00275457</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks Followed by 46 Weeks Open-label or Double-blind Treatment Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from
      moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 week
      open label or double blind extension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from
      moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 weeks
      open label or double blind extension

      Study Hypotheses:

      Null hypothesis: No difference between pramipexole and placebo in RLSRS total score from
      baseline and no difference in the CGI-I responder rates at the end of the 6 weeks
      double-blind treatment.

      Comparison(s):

      Pramipexole vs. Placebo
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date>April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline to week 6 on the RLSRS +</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>CGI-I responders (much and very much improved)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>RLRS responders, CGI, PGI responders, EPSS, QoL (SF-36) VAS severity of RLS</measure>
  </secondary_outcome>
  <enrollment>346</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female out-patients aged 18-80

          2. Diagnosis of idiopathic RLS according to the Clinical RLS criteria of the
             International RLS Study Group. All of the four criteria must be present:

               -  Irresistible urge to move usually associated with sensory complaints of the lower
                  limbs

               -  Motor restlessness

               -  Worsening of the symptoms at rest with at least partial and temporary relief by
                  activity

               -  Increased severity in the evening or at night

          3. RLS rating scale for severity score &gt; 15

          4. RLS symptoms present at least 2 to 3 days per week within in the last 3 months

          5. Written informed consent consistent with ICH/GCP and local legislation given prior to
             any study procedures

          6. Ability and willingness to comply with study treatment regimen and to attend study
             assessments

        Exclusion criteria:

          1. Women of childbearing potential, who do not use adequate protection such as barrier
             protection, intrauterine device, or hormonal (oral or subcutaneous) contraception or
             postmenopausal women less than 6 months after last menses, surgically sterilised,
             oophorectomised or hysterectomised less than 3 months after operation and not using
             adequate protection or women neither using adequate protection nor being
             postmenopausal and their partner is not sterilised at least 6 months post operation or
             does not use condom, or any women not having negative serum pregnancy test at
             screening

          2. Males not using an adequate form of contraception (condom, sterilisation at least 6
             months post operation)

          3. Patients who are breastfeeding

          4. Concomitant or previous pharmacologically therapy of RLS as follows:

               -  Any intake of levodopa within 5 days prior to baseline visit (V2)

               -  Any intake of dopamine agonists within 14 days prior to baseline visit (V2)

               -  History of any intake of pramipexole

          5. Current (less than 14 days before treatment with trial medication or concomitant)
             treatment with medication or dietary supplements, which could significantly influence
             RLS symptoms - withdrawal symptoms caused by stopping any of the drugs above

          6. Confirmed diagnose of diabetes mellitus requiring insulin therapy

          7. Clinically significant renal disease or creatinine higher than upper limit of normal
             (ULN) at screening

          8. Clinically significant hepatic disease or sGPT &gt; 2 times the upper limit of normal
             range at screening

          9. Clinical or laboratory signs of microcytic anaemia at the investigators discretion

         10. Any of the following lab results at screening:

               -  Hb or erythrocyte count below lower limit of normal (LLN)

               -  Basal TSH, T3 or T4 clinically significantly (at the investigator's discretion)
                  out of normal range at screening (if not caused by substitution therapy according
                  the investigator's opinion)

         11. Other clinically significant metabolic-endocrine, haematological, gastro-intestinal
             disease or pulmonary disease. Poorly controlled cardiovascular disease

         12. History or clinical signs of peripheral neuropathy (PNP) of any origin in physical,
             neurological examination, myelopathy or multiple sclerosis or any other neurological
             disease, with potential to secondarily cause RLS symptoms

         13. Presence of any other sleep disorder, such as, REM sleep behaviour disorder,
             narcolepsy or sleep apnoea syndrome

         14. History of Schizophrenia or any psychotic disorder, history of mental disorders due to
             a general medical condition or any present axis I psychiatric disorder according DSM
             IV requiring any medical therapy or history of or alcohol abuse or drug addiction
             within the last 2 years before screening

         15. Participation in a drug study within two months prior to the start of this study

         16. History of or clinical signs for any form of epilepsy or seizures apart from fever
             related seizures in early childhood

         17. History of or clinical signs of malign neoplasm

         18. Patients on a shift-work-schedule, or who are otherwise unable to follow a regular
             sleep-wake cycle enabling use of study medication at times indicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>B.I. Pharma GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ.-Klinik für Neurologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.-Klinik für Neurologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Confraternität Privatklinik</name>
      <address>
        <city>Wien</city>
        <zip>1080</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Universitätsklinik für Psychiatrie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sonderkrankenanstalt für neurologischen und</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Dürrheim-Sunthausen</city>
        <zip>78073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Neurologie</name>
      <address>
        <city>Emmendingen</city>
        <zip>79312</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kehl</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH &amp; Co. KG</name>
      <address>
        <city>Leipzig</city>
        <zip>04229</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen und Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beek en Donk</city>
        <zip>5741 AR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2585 LJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deurne</city>
        <zip>5751 XJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ewijk</city>
        <zip>6644 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lichtenvoorde</city>
        <zip>7131 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rijswijk</city>
        <zip>2281 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roelofarendsveen</city>
        <zip>2371 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3082 DC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>N-2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>N-0159</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>N-0303</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tønsberg</city>
        <zip>N-3111</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stockholms Neuro Center</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologkliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Läkarhuset Vällingby</name>
      <address>
        <city>Vällingby</city>
        <zip>162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Västra Frölunda</city>
        <zip>421 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2006</study_first_submitted>
  <study_first_submitted_qc>January 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2006</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

